Extended Partnership
Pharmaceuticals

Safic-Alcan Extends Strategic Collaboration with Ashland in France

Published on November 20, 2025

Safic-Alcan extends strategic collaboration with Ashland for pharmaceutical and nutraceutical ingredients in France.

Paris, La Défense, 2023 – Safic-Alcan, a global distributor of specialty chemicals and ingredients, proudly announces the extension of its long-standing strategic collaboration and distribution agreement with Ashland, a world leader in additives and specialty ingredients. Beginning November 1st, 2023, Safic-Alcan will distribute Ashland’s pharmaceutical and nutraceutical ingredients portfolio in France.

This strengthened collaboration follows the success of Safic-Alcan and Ashland’s partnership in Spain and Portugal, reinforcing their joint commitment to delivering innovative, high-quality solutions for the life sciences sector.

A Comprehensive Pharmaceutical Ingredient Portfolio

The expanded agreement includes several market-leading Ashland solutions widely used in pharmaceutical and nutraceutical formulations, such as:

  • Plasdone™ (povidone)
  • Polyplasdone™ (crospovidone)
  • Klucel™ (hydroxypropylcellulose)
  • Benecel™ (hydroxypropylmethylcellulose)
  • Natrosol™ (hydroxyethylcellulose)

These high-performance ingredients are recognized globally for their stability, functionality, and versatility in solid dosage forms, controlled release systems, and nutritional products.

Tomas Navarro, Ashland’s General Manager for Life Sciences in EMEA, stated:

Ashland and Safic-Alcan have been building a strategic business relationship focused on life sciences markets in Spain and Portugal. We now look forward to extending our strategic collaboration with Safic-Alcan in France to deliver premium service to our customers in the region.
Tomas NavarroGeneral Manager for Life Sciences in EMEAAshland

Jose Lora, Life Sciences Managing Director at Safic-Alcan, added:

Our continued partnership with Ashland signifies a commitment to excellence and innovation. With a successful track record in Iberia as Ashland's long-standing distributor, we are elated to expand this strategic collaboration to the vibrant pharmaceutical landscape of France.
Jose LoraLife Sciences Managing Director Safic-Alcan

Gaël Garnaud, Pharmaceuticals and Animal Nutrition Business Development Director at Safic-Alcan, emphasized:

France represents a significant market for us, and we are dedicated to optimizing it. By strengthening our customer relationships and leveraging Ashland’s cutting-edge technologies, we reaffirm the evolution of our long-term partnership and our shared commitment to progress and customer satisfaction.
Gaël GarnaudPharmaceuticals and Animal Nutrition Business Development DirectorSafic-Alcan

Setting New Standards in Pharmaceutical and Nutraceutical Distribution

As established leaders in their respective fields, Safic-Alcan and Ashland are poised to elevate pharmaceutical and nutraceutical ingredient distribution in France. This extended partnership reinforces both companies’ dedication to innovation, service excellence, and strategic growth.

About Safic-Alcan
Safic-Alcan is a French independent distributor of specialty chemicals headquartered in Paris La Défense. The company supplies polymers, materials, and additives across numerous industries, including rubber, coatings, adhesives, thermoplastics, polyurethane, lubricants, detergency, cosmetics, pharmaceuticals, and nutraceuticals.
With 35 offices, 780 employees, and a 2022 turnover of €907M, the group maintains strong, long-term partnerships supported by deep technical expertise. Learn more.

About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company dedicated to innovation and backed by strong ESG values. Serving customers in more than 100 countries, Ashland delivers high-performance solutions for architectural coatings, construction, energy, food & beverage, nutraceuticals, personal care, and pharmaceuticals. Its 3,900+ employees work to solve complex challenges with practical, elegant solutions. Learn more.

Discover our Pharmaceuticals market